This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $323,000.00 to the Rector & Visitors of the University of Virginia (UVA) to investigate the role of glucose-6-phosphate dehydrogenase (G6PD) deficiency in atherosclerosis development.
The key objectives are to test the hypothesis that G6PD deficiency promotes atherosclerosis by affecting B cell subsets and their production of protective immunoglobulin M (IgM) antibodies against oxidation-specific epitopes. The research will utilize a novel humanized mouse model expressing a common G6PD deficiency mutation to examine the underlying mechanisms. Findings from this project could elucidate how G6PD deficiency, which affects approximately 500 million people worldwide, may contribute to increased cardiovascular disease risk. The award has an effective date of Mar 4, 2025 and a completion date of Dec 31, 2027.
Generated 3/25/25, 3:25 AM